肺纤维化附加疗法,即将到来的时代对实践有影响:BI 101550和RELIEF试验
Lurdes Planas-Cerezales1,2,3, Laura Fabbri4,3, Laurence Pearmain5,6
1Respiratory Department, Hospital de Viladecans, Barcelona, Spain.
Breathe (Sheffield, England)
|September 18, 2023
概括
最近的两项试验,BI 101550和RELIEF,探讨了针对异常性肺纤维化 (IPF) 和渐进性纤维化间歇性肺病 (PFILD) 的补充抗纤维治疗方法. 这两项试验都满足了主要终点,显示了对管理这些复杂的纤维化肺部疾病的新疗法选择的希望.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 异形性肺纤维化 (IPF) 和渐进性纤维化间歇性肺病 (PFILD) 的治疗正在随着新的抗纤维化疗法而发展.
- 对于患者的病情进展,尽管第一线治疗,正在研究附加治疗.
研究的目的:
- 审查和对BI 101550和RELIEF试验的结果进行上下文化,这些试验评估了新的抗纤维素补充剂选择.
- 讨论这些试验结果在当前治疗环境中的优点,弱点,临床影响和影响.
主要方法:
- 对两个2期随机对照试验 (RCT) 的审查:IPF中的BI 101550和PFILD中的RELIEF.
- 主要终点集中在不同时间段的强迫活力能力 (FVC) 变化上 (BI 101550的12周,RELIEF的48周).
主要成果:
- 在BI 101550试验中,IPF患者的新型固酶-4抑制剂呈阳性结果.
- 此外,RELIEF试验在PFILD患者中也显示了其主要终点的积极结果,这些患者接受了皮尔芬尼治疗.
- 这两项试验都达到各自的初级疗效终点,表明研究疗法的潜在益处.
结论:
- BI 101550和RELIEF试验代表了IPF和PFILD的补充抗纤维菌疗法探索的重大进展.
- 讨论试验的局限性和优势对于准确的解释和临床应用至关重要.
- 需要进一步的研究和临床评估,才能充分理解这些药物在治疗纤维化肺部疾病中的作用.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
241
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
241
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
210
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
210
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
256
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
256
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K


